Q4 Results Today: What to expect from L&T, Dr Reddy’s, Godrej Consumer

May 10, 2023

Several Indian companies, including Larsen & Toubro, Godrej Consumer Products, and Dr Reddy’s Laboratories, are expected to record double-digit growth in their topline and bottomline figures for the March quarter due to healthy execution and strong order books. L&T’s core engineering business is expected to drive the topline with a healthy opening order book. Meanwhile, Revlimid, the cancer drug, is expected to have contributed significantly to growth in Dr Reddy’s US sales.

More To Explore

Suzlon Energy shares up 13.6% on rising profits

Suzlon Energy’s shares experienced a significant surge. This followed the company’s report of a fourfold profit increase for the March quarter. The company’s market capitalization

May 31, 2025

At 7.4%, India’s growth steps on race pedal in Q4

India’s economy surpassed expectations with a 7.4% growth in the March quarter, boosting FY25 growth to 6.5%. Investment recovery and strong construction drove this expansion,

May 31, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003